BioSig to Participate at The 14th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy
October 10 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM), a medical technology
company developing a proprietary biomedical signal processing
platform designed to improve signal fidelity and uncover the full
range of ECG and intra-cardiac signals, today announced that the
Company will be exhibiting at the 14th Annual International
Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy
on October 11-12, 2019 at Hyatt at the Bellevue in Philadelphia,
PA.
The symposium is co-hosted by the Department of Medicine,
Division of Cardiology, University of Pennsylvania Health System,
Philadelphia, PA and the Division of Cardiology, The Mount Sinai
Hospital, New York, NY. This course has been developed to meet the
educational needs of electrophysiologists, cardiologists and other
physicians and associated professionals with an interest in the
pathophysiology and management of ventricular arrhythmias.
BioSig will be represented by its clinical, marketing and
commercial teams.
Previously, BioSig announced that it successfully conducted
first patient cases using PURE EPTM System at the Texas
Cardiac Arrhythmia Institute in Austin, TX, Greenville Memorial
Hospital in Greenville, SC and Indiana University School of
Medicine. Initial clinical data collected with PURE EPTM
System was recently presented at the Venice Arrhythmias
conference, which took place on October 3-5, 2019 in Venice,
Italy.
“We are honoured to join such a prestigious industry event and
contribute to one of the core objectives of the symposium, which
includes a discussion about the new techniques and technologies to
improve treatment outcomes in patients with complex arrhythmias.
Participation at the leading industry conferences is a vital part
of our launch strategy, and we look forward to expanding our
clinical footprint and sharing more clinical data in the months to
come,” commented Olivier Chaudoir, Director of Marketing of BioSig
Technologies, Inc.
BioSig was recently added to the Russell 3000 Index and allowed
33 patent claims covering its PURE EPTM System.
The PURE EP TM System is a computerized system intended for
acquiring, digitizing, amplifying, filtering, measuring and
calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The PURE EPTM System aims to minimize noise and artifacts and
acquire high-fidelity cardiac signals. Improving fidelity of
acquired cardiac signals may potentially increase the diagnostic
value of these signals, thereby possibly improving accuracy and
efficiency of the EP studies and related procedures. The results of
pre-clinical studies have been published in a number of
journals, including The Journal of Innovations in Cardiac
Rhythm Management and the Journal of the American College of
Cardiology, a manuscript, which was included in the top 5 most
read, discussed and shared articles in 2016. About 14th
Annual International Symposium on Ventricular
Arrhythmias
According to the Symposium’s website, the purpose of this
educational activity is to provide a current review of new
information on the basic pathophysiology of ventricular
arrhythmias. It is also designed to provide an in-depth
understanding of the various management strategies that are
currently being developed for the management of ventricular
arrhythmias in various disease states, including non-pharmacologic
therapies such as implantable device therapy and advances in
catheter ablation techniques.
About BioSig Technologies BioSig Technologies
is a medical technology company developing a proprietary biomedical
signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com). Led by a
proven management team and a veteran Board of Directors, BioSig
Technologies is preparing to commercialize its PURE EPTM System.
The technology has been developed to address an unmet need in a
large and growing market.
The Company’s first product, PURE EPTM System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The system is indicated for use under the supervision of licensed
healthcare practitioners who are responsible for interpreting the
data. This novel cardiac signal acquisition and display system is
engineered to assist electrophysiologists in clinical
decision-making during electrophysiology procedures in patients
with abnormal heart rates and rhythms. BioSig’s ultimate goal is to
deliver technology to improve upon catheter ablation treatments for
the prevalent and potentially deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with
Minnetronix on technology development and received FDA 510(k)
clearance for the PURE EPTM System in August 2018.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
TM
Natasha Drapeau
BioSig Technologies, Inc.
Executive Vice President
54 Wilton Road, 2nd floor
Westport, CT 06880
ndrapeau@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024